Literature DB >> 19800142

Chromosomal aberrations in peripheral blood lymphocytes of prostate cancer patients treated with IMRT and carbon ions.

Carola Hartel1, Anna Nikoghosyan, Marco Durante, Sylwester Sommer, Elena Nasonova, Claudia Fournier, Ryonfa Lee, Jürgen Debus, Daniela Schulz-Ertner, Sylvia Ritter.   

Abstract

BACKGROUND AND
PURPOSE: To investigate the cytogenetic damage in blood lymphocytes of patients treated for prostate cancer with different radiation qualities and target volumes.
MATERIALS AND METHODS: Twenty patients receiving carbon-ion boost irradiation followed by IMRT or IMRT alone for the treatment of prostate cancer entered the study. Cytogenetic damage induced in peripheral blood lymphocytes of these patients was investigated at different times during the radiotherapy course using Giemsa staining and mFISH. A blood sample from each patient was taken before initiation of radiation therapy and irradiated in vitro to test for individual radiosensitivity. In addition, in vitro dose-effect curves for the induction of chromosomal exchanges by X-rays and carbon ions of different energies were measured.
RESULTS: The yield of chromosome aberrations increased during the therapy course, and the frequency was lower in patients irradiated with carbon ions as compared to patients treated with IMRT with similar target volumes. A higher frequency of aberrations was measured by increasing the target volume. In vitro, high-LET carbon ions were more effective than X-rays in inducing aberrations and yielded a higher fraction of complex exchanges. The yield of complex aberrations observed in vivo was very low.
CONCLUSION: The investigation showed no higher aberration yield induced by treatment with a carbon-ion boost. In contrast, the reduced integral dose to the normal tissue is reflected in a lower chromosomal aberration yield when a carbon-ion boost is used instead of IMRT alone. No cytogenetic "signature" of exposure to densely ionizing carbon ions could be detected in vivo. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800142     DOI: 10.1016/j.radonc.2009.08.031

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

Review 1.  New challenges in high-energy particle radiobiology.

Authors:  M Durante
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

2.  Harnessing radiation to improve immunotherapy: better with particles?

Authors:  Marco Durante; Silvia Formenti
Journal:  Br J Radiol       Date:  2019-07-22       Impact factor: 3.039

Review 3.  Assessing the risk of second malignancies after modern radiotherapy.

Authors:  Wayne D Newhauser; Marco Durante
Journal:  Nat Rev Cancer       Date:  2011-05-19       Impact factor: 60.716

Review 4.  Carbon Ion Radiobiology.

Authors:  Walter Tinganelli; Marco Durante
Journal:  Cancers (Basel)       Date:  2020-10-17       Impact factor: 6.575

5.  Ionizing Radiation Impacts on Cardiac Differentiation of Mouse Embryonic Stem Cells.

Authors:  Alexander Helm; Onetsine Arrizabalaga; Diana Pignalosa; Insa S Schroeder; Marco Durante; Sylvia Ritter
Journal:  Stem Cells Dev       Date:  2015-12-14       Impact factor: 3.272

6.  Impact of Charged Particle Exposure on Homologous DNA Double-Strand Break Repair in Human Blood-Derived Cells.

Authors:  Melanie Rall; Daniela Kraft; Meta Volcic; Aljona Cucu; Elena Nasonova; Gisela Taucher-Scholz; Halvard Bönig; Lisa Wiesmüller; Claudia Fournier
Journal:  Front Oncol       Date:  2015-11-11       Impact factor: 6.244

7.  Comparison of Individual Radiosensitivity to γ-Rays and Carbon Ions.

Authors:  Grace Shim; Marie Delna Normil; Isabelle Testard; William M Hempel; Michelle Ricoul; Laure Sabatier
Journal:  Front Oncol       Date:  2016-06-13       Impact factor: 6.244

8.  Persistence of radiation-induced aberrations in patients after radiotherapy with C-ions and IMRT.

Authors:  Carola Hartel; Elena Nasonova; Martina C Fuss; Anna V Nikoghosyan; Juergen Debus; Sylvia Ritter
Journal:  Clin Transl Radiat Oncol       Date:  2018-10-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.